NCT02274415View on ClinicalTrials.gov

Immunogenicity Study of an Anti-pneumococcal Vaccination Strategy in Patients With Sickle Cells Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

September 16, 2013

Primary Completion Date

September 18, 2017

Study Completion Date

April 10, 2019

Conditions
Invasive Pneumococcal InfectionsSickle Cells Disease
Interventions
BIOLOGICAL

Vaccination with the combined vaccine (Prevenar13 ®)

BIOLOGICAL

Vaccination with the polysaccharide vaccine (Pneumo 23 ®)

Trial Locations (1)

94010

Henri Mondor Hospital, Créteil

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT02274415 - Immunogenicity Study of an Anti-pneumococcal Vaccination Strategy in Patients With Sickle Cells Disease | Biotech Hunter | Biotech Hunter